Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

http://www.wikidata.org/entity/Q33687554

about

The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer Revolutionizing Alzheimer's disease and clinical trials through biomarkers Unfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion Diseases The genetic landscape of Alzheimer disease: clinical implications and perspectives Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?Monitoring of 30 marker candidates in early Parkinson disease as progression markers.Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study d-serine levels in Alzheimer's disease: implications for novel biomarker development The sleep-wake cycle and Alzheimer's disease: what do we know?Tau PET imaging: present and future directions.Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers.Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models.Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis.Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings Age-dependent inverse correlations in CSF and plasma amyloid-β(1-42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study.Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Alzheimer's disease genetics: from the bench to the clinic.Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.

P2860

Q26738703-B0717600-B4DA-4D43-9D77-056208C2EBA2 Q26744882-0D534843-ACC4-4702-A38B-C8C19B7E48FF Q26773443-120928EB-F41A-4295-99E1-89BF32E8B15C Q26796582-71985B9D-4153-48F4-BD48-24DFFD2A0F31 Q26801666-31DE0C9C-AEF8-46C2-AE6F-C68AFE79F49F Q30275974-D07790E8-F6AA-44B9-951F-ECF1A7BB998C Q30783504-9C6877C5-0A6A-4F60-B3FB-3D4B56C81000 Q30981669-F874DA7D-DDEB-4450-8983-A43B6CAC0631 Q33769278-E017EABD-E00F-4AC7-8E9D-8513F65DD069 Q33894452-356FC737-CAA1-412E-A7C0-ACD305D2180C Q34475073-E568497B-141E-45F3-877D-66B414F554F3 Q34637928-5962D130-7D6F-494C-84E9-94A27F2E00D9 Q34680852-3248AD04-C47E-445D-AB1F-D2C72B5C3808 Q35073049-EDE9D5FB-7CE9-4875-BADB-16854EAEA229 Q35164302-4BE19E6B-5224-4A42-8B82-2BAB27985407 Q35540628-B518C413-ADB5-4F20-BA81-991CFD567692 Q35795155-E6EDB57B-917E-4D13-A55E-DAB564168365 Q35800785-D81DAA03-4A3C-4539-9979-BBB38C1CEBAE Q35900301-E86794FC-99E9-4898-B97A-01A75790D9EE Q35904243-03ADF5A0-9DC1-45EE-8713-FF508D7B6C43 Q36001286-013B199E-DFE2-4255-B6F7-341CD98F346C Q36017239-0E326293-65DD-41DE-99F5-564AC8534195 Q36062391-378C6B5A-B186-4CDB-AD6F-9E157774E0B2 Q36071742-E613B172-31D8-46F4-A7E2-A1116AD1DE65 Q36105614-DB94D186-94A6-428A-934B-388915B2B179 Q36165011-9A86B4E8-230B-46A0-8F76-6B38E71C7E0C Q36209842-3E960FE7-7E0C-409D-8DBC-D20AD011AE34 Q36276506-820D1C0E-1649-4F7B-9170-47E929AA504A Q36305487-2B58A8DC-316D-46B1-85EB-2386C7FDDC77 Q36528218-208EB632-C7B3-46EE-8392-E73DFD090921 Q36739111-CF85B96E-F25B-4F27-B45D-58B605AFF92A Q36806654-E96841FD-9ABE-4B5E-AA7C-980F375D3535 Q36813260-D7E5C78C-F3A5-4C78-A024-17D54ED1F7D7 Q36933698-BAA12C18-36E8-496B-BEB6-F4D29A4204F8 Q37067687-FD406746-A5CC-4F09-9C87-A815B657B78E Q37272348-1D92A20A-5E5F-4506-8516-9DF30CEF8F60 Q37743591-CD9AD5D0-EF4F-4F0C-9939-31D2CF41E329 Q38224958-A939674D-8423-4CF8-9871-404118822700 Q38225911-CC83B7D7-F554-4C6D-BC2A-4D0BD455FFF8 Q38235780-F075B4AC-21E0-44BD-84C0-03DC20352DEE

P2860

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

http://www.wikidata.org/entity/Q33687554

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

@ast

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

@en

type

label

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

@ast

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

@en

prefLabel

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

@ast

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

@en

P1433

Q33687554-F7DCCCEE-5D14-4E76-9F85-119ECCFC1040

P1476

Q33687554-ED158E21-654A-4521-897E-869381C76BBC

P2093

Q33687554-2EDF5AFF-CCAB-46AC-BC23-7B28923291FC

Q33687554-4C0FDB37-28D3-44F6-BF96-FE25EDAFF13C

Q33687554-4F231B86-7816-4964-B533-D5700563CC48

Q33687554-578860B5-146E-4167-B9CF-9FD197B338D2

Q33687554-5C35B82D-F9FE-440F-9F55-7FC009E8783D

Q33687554-73CB5724-8753-4639-B7FB-3D56C86EBCAC

Q33687554-91A569A6-2254-455F-901C-59E7B99AD87A

Q33687554-9A691D6E-6263-4A98-B0A8-FEC9F8E2ADF6

Q33687554-D153567B-C8A0-475F-AA8C-806A6F715332

Q33687554-D58960CD-CFE3-4C22-B0D8-D3AA2EDB0EC5

P2860

Q33687554-00D332D5-CB45-476C-83FB-76D24F4D4148

Q33687554-019FE93C-2523-4891-A39F-1C4868B16452

Q33687554-02267E57-5EC7-4B4E-8922-4F847DC7BE5C

Q33687554-0CD1625A-07B2-4F46-B418-FE8A2E3833DA

Q33687554-0F6F4832-B808-4B0E-A5D2-B8E55CE6C18B

Q33687554-1045A095-ADAF-436A-9568-CDB8D5F704A1

Q33687554-1CD8455F-A981-4EC0-B362-19771D07B081

Q33687554-20A1A9AC-103A-4650-8C7B-51AE5A50D7DB

Q33687554-283D01F9-84CE-438E-86AA-3EF5054CD6EE

Q33687554-2A5E775F-CE91-4255-AE81-3BD6D0B2E39E

P304

Q33687554-658146BF-C55D-4D71-BD4B-2B8CFBE625FC

P31

Q33687554-A9435892-8FB5-460D-923B-6F4C6DD64CE6

P356

Q33687554-38FDE409-7A50-43E0-BF55-4F54054EDA17

P407

Q33687554-33D0419A-0B81-411F-AFA6-D3B6C8FC6070

P433

Q33687554-2A3E1B72-BBEA-4078-9DEE-529C437AE4C7

P478

Q33687554-E25C1CF7-7C20-42C2-BE67-200A163DC2CF

P50

Q33687554-0F24321B-227E-4C49-B924-220AEBF5C73F

Q33687554-1DEEB7E1-D150-44C8-8119-CBC3823C8868

Q33687554-32505C3B-A3FB-4050-8138-59762CDB16BA

Q33687554-48FAB60C-6917-4CC0-B8AB-C492B62BEECC

Q33687554-5311300F-469D-4630-A1B4-3B51CC9E4D6F

Q33687554-596FB0EC-A258-4C3E-AA9B-5A2039447FE5

Q33687554-99F93A25-D697-406D-90A5-CBA2366DDA75

Q33687554-A09B875F-7F4B-4383-866A-BFF5C2EB4881

Q33687554-AEE2B5BE-E124-4577-8A83-46E15D8B627C

Q33687554-E39259FA-379E-4BC3-84AA-ECB862268D4B

P577

Q33687554-433FFBAA-1015-43AE-981A-2D0CE0B77366

P5875

Q33687554-025410B3-D2B6-4344-916A-DA578FA08960

P698

Q33687554-BDC9FF8C-12F5-425B-9D49-D56C2BB3F912

P921

Q33687554-09210997-D273-430E-9DDE-99975FAD771E

Q33687554-9B747F33-DECC-4CE0-9A28-8EF83DBEDF6D

P932

Q33687554-D71833C9-6248-4216-905A-BE5A5A128A1D

P356

SCITRANSLMED.3007901

P1433

Science Translational Medicine

P1476

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

@en

P2093

Bernardino Ghetti

http://www.w3.org/2001/XMLSchema#string

Chengjie Xiong

http://www.w3.org/2001/XMLSchema#string

Daniel Marcus

http://www.w3.org/2001/XMLSchema#string

Jack H Ladenson

http://www.w3.org/2001/XMLSchema#string

John M Ringman

http://www.w3.org/2001/XMLSchema#string

Mateusz S Jasielec

http://www.w3.org/2001/XMLSchema#string

Nigel J Cairns

http://www.w3.org/2001/XMLSchema#string

Reisa A Sperling

http://www.w3.org/2001/XMLSchema#string

Stephen Salloway

http://www.w3.org/2001/XMLSchema#string

Tammie L S Benzinger

http://www.w3.org/2001/XMLSchema#string

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Random-effects models for longitudinal data

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

The Clinical Dementia Rating (CDR): current version and scoring rules

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Atrophy rates accelerate in amnestic mild cognitive impairment.

P304

226ra30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3007901

http://www.w3.org/2001/XMLSchema#string

P407

P433

226

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Colin L. Masters

Peter R Schofield

Randall J. Bateman

David M. Holtzman

Dominantly Inherited Alzheimer Network

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262046669

http://www.w3.org/2001/XMLSchema#string

P698

24598588

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4038930

http://www.w3.org/2001/XMLSchema#string